XELJANZ 1 mg/mL oral solution

DRUG3 trials

Sponsors

Pfizer Inc., IRCCS Istituto Giannina Gaslini, Duke Clinical Research Institute

Conditions

Juvenile Idiopathic ArthritisJuvenile idiopathic arthritisUlcerative Colitis (UC)

Phase 3

A3921210 - OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

RecruitingCTIS2023-509694-22-00

Pfizer Inc.Ulcerative Colitis (UC)

Start: 2022-01-26Target: 37Updated: 2025-09-01

Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA)

Not yet recruitingCTIS2025-520923-25-00

Duke Clinical Research InstituteJuvenile Idiopathic Arthritis

Target: 30Updated: 2026-02-11

Phase 4

Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized clinical trial comparing early versus late drug withdrawal combining imaging and multi-Omics.

RecruitingCTIS2024-514732-24-00

IRCCS Istituto Giannina GasliniJuvenile idiopathic arthritis

Start: 2025-04-28Target: 328Updated: 2025-08-26